IOVA vs. IMVT, SWTX, KRYS, CRSP, IMCR, ACLX, HALO, TWST, DNLI, and VCEL
Should you be buying Iovance Biotherapeutics stock or one of its competitors? The main competitors of Iovance Biotherapeutics include Immunovant (IMVT), SpringWorks Therapeutics (SWTX), Krystal Biotech (KRYS), CRISPR Therapeutics (CRSP), Immunocore (IMCR), Arcellx (ACLX), Halozyme Therapeutics (HALO), Twist Bioscience (TWST), Denali Therapeutics (DNLI), and Vericel (VCEL). These companies are all part of the "biological products, except diagnostic" industry.
Immunovant (NASDAQ:IMVT) and Iovance Biotherapeutics (NASDAQ:IOVA) are both mid-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their community ranking, profitability, media sentiment, institutional ownership, earnings, risk, valuation, dividends and analyst recommendations.
Immunovant has higher earnings, but lower revenue than Iovance Biotherapeutics. Immunovant is trading at a lower price-to-earnings ratio than Iovance Biotherapeutics, indicating that it is currently the more affordable of the two stocks.
Iovance Biotherapeutics received 449 more outperform votes than Immunovant when rated by MarketBeat users. However, 76.22% of users gave Immunovant an outperform vote while only 74.50% of users gave Iovance Biotherapeutics an outperform vote.
Immunovant currently has a consensus price target of $48.00, suggesting a potential upside of 63.32%. Iovance Biotherapeutics has a consensus price target of $24.64, suggesting a potential upside of 124.68%. Given Immunovant's higher probable upside, analysts plainly believe Iovance Biotherapeutics is more favorable than Immunovant.
47.1% of Immunovant shares are owned by institutional investors. Comparatively, 77.0% of Iovance Biotherapeutics shares are owned by institutional investors. 4.8% of Immunovant shares are owned by insiders. Comparatively, 10.4% of Iovance Biotherapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
In the previous week, Iovance Biotherapeutics had 17 more articles in the media than Immunovant. MarketBeat recorded 24 mentions for Iovance Biotherapeutics and 7 mentions for Immunovant. Iovance Biotherapeutics' average media sentiment score of 0.84 beat Immunovant's score of 0.58 indicating that Immunovant is being referred to more favorably in the media.
Immunovant has a net margin of 0.00% compared to Immunovant's net margin of -23,615.70%. Iovance Biotherapeutics' return on equity of -57.97% beat Immunovant's return on equity.
Immunovant has a beta of 0.7, meaning that its share price is 30% less volatile than the S&P 500. Comparatively, Iovance Biotherapeutics has a beta of 0.66, meaning that its share price is 34% less volatile than the S&P 500.
Summary
Immunovant and Iovance Biotherapeutics tied by winning 8 of the 16 factors compared between the two stocks.
Get Iovance Biotherapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for IOVA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding IOVA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Iovance Biotherapeutics Competitors List
Related Companies and Tools
